Show simple item record

dc.contributor.authorNart Molina, José
dc.contributor.authorJiménez-Garrido, Sara
dc.contributor.authorRamírez Sebastià, Anaïs
dc.contributor.authorAstó, Erola
dc.contributor.authorBuj, David
dc.contributor.authorHuedo, Pol
dc.contributor.authorEspadaler Mazo, Jordi
dc.date.accessioned2021-06-01T17:06:16Z
dc.date.available2021-06-01T17:06:16Z
dc.date.issued2021
dc.identifier.citationNart Molina, José; Jiménez-Garrido, Sara; Ramírez-Sebastià, Anaïs [et al.]. Oral colonization by levilactobacillus brevis KABPTM-052 and Lactiplantibacillus plantarum KABPTM-051: a randomized, double-blinded, placebo-controlled trial (pilot study). Journal of Clinical and Experimental Dentistry, 2021, 13(5), e433-439. Disponible en: <https://www.medoraljced.com/jced/revista/2021/May/13/>. Fecha de acceso: 1 jun. 2021. DOI: 10.4317/jced.57771en
dc.identifier.issn1989-5488ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2578
dc.description.abstractBackground: To determine the oral colonization capacity of the strains Levilactobacillus brevis KABPTM-052 (CECT 7480) and Lactiplantibacillus plantarum KABPTM-051 (CECT 7481) in healthy subjects. Material and Methods: This randomized, double-blinded, placebo-controlled study included 40 volunteers (22 females, 18 males; age range 18-55 years) with healthy gingiva or mild gingivitis, allocated to receiving probiotic chewing gum (n=20) or placebo (n=20) b.i.d for 6 weeks. At baseline and after 6 weeks of treatment, a periodontics specialist collected saliva samples to assess probiotic colonization by qPCR, and analysed dental plaque, gingival index and dental probing pocket depth in Community Periodontal Index (CPI) teeth subset. Protocol was registered as NCT03540498. Results: Treatment compliance was high (99%). Both L. brevis and L. plantarum were detected in the oral microbiota at baseline. After 6 weeks, volunteers receiving probiotic showed a significant increase of both L. brevis (p = 0.017) and L. plantarum (p = 0.004) versus placebo. This effect remained significant after adjusting for gender and gingival index at baseline. In the probiotic group, reduction in plaque index significantly correlated to higher levels of L. brevis (rho = 0.57, p = 0.022) but not of L. plantarum at study endpoint, and the number of subjects with dental plaque was reduced during intervention (7 of 17, p = 0.016). No such effects were observed in the placebo group. No adverse drug reactions were reported. Conclusions: Levilactobacillus brevis KABPTM-052 and Lactiplantibacillus plantarum KABPTM-051 colonize the buccal microbiota of healthy volunteers, and higher colonization by L. brevis positively correlated to reduction in dental plaque.en
dc.format.extent7ca
dc.language.isoengca
dc.publisherMedicina Oral S.L.ca
dc.relation.ispartofJournal of Clinical and Experimental Dentistryca
dc.relation.ispartofseries13;5
dc.rights© 2021 Medicina Oral S.L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherProbiòticsca
dc.subject.otherOdontologiaca
dc.subject.otherPeriodònciaca
dc.subject.otherSalivaca
dc.subject.otherMicrobiota oralca
dc.subject.otherPlaca dentalca
dc.subject.otherProbióticoses
dc.subject.otherOdontologíaes
dc.subject.otherPeriodonciaes
dc.subject.otherSalivaes
dc.subject.otherMicrobiota orales
dc.subject.otherPlaca dentales
dc.subject.otherProbioticsen
dc.subject.otherDentistryen
dc.subject.otherPeriodonticsen
dc.subject.otherSalivaen
dc.subject.otherOral microbiotaen
dc.subject.otherDental plaqueen
dc.titleOral colonization by levilactobacillus brevis KABPTM-052 and Lactiplantibacillus plantarum KABPTM-051: a randomized, double-blinded, placebo-controlled trial (pilot study)en
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc616.3ca
dc.identifier.doihttps://dx.doi.org/10.4317/jced.57771ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© 2021 Medicina Oral S.L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint